SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007; 204: 956962; discussion 962–963.
  • 2
    Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005; 128: 18051811.
  • 3
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 24622476. Erratum in: N Engl J Med. 2006;18;354:2200.
  • 4
    Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol. 2004; 16: 11671171.
  • 5
    Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol. 2006; 40: 476481.
  • 6
    Probert CSJ, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticosteroid resistant ulcerative colitis. A randomized controlled trial. Gut. 2003; 52: 9981002.
  • 7
    Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomosis complications and function in 1005 patients. Ann Surg. 1995; 222: 120127.
  • 8
    Rugeerts P, d'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factory antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999; 117: 761769.
  • 9
    Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agents. N Engl J Med. 2001; 345: 10981104.
  • 10
    Colombel J-F, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004; 126: 1931.
  • 11
    Ljung T, Karlén P, Schmidt D, et al. Infliximab in inflammatory bowel disease: Clinical outcome in a population based cohort from Stockholm County. Gut. 2004; 53: 849853.
  • 12
    Arseneau KO, Sultan S, Provenzale DT, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol. 2006; 4: 11351142.
  • 13
    Lichtenstein GR, Feagan B, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006; 4: 621630.
  • 14
    Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004; 99: 878883.
    Direct Link:
  • 15
    Marchal L, D'Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: A controlled cohort study. Aliment Pharmacol Ther. 2004; 19: 749754.
  • 16
    Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum. 2007; 50: 17471753.
  • 17
    Dhillon S, Loftus EV Jr, Tremaine WJ, et al. The natural history of surgery for ulcerative colitis in a population-based cohort from Olmsted County, Minnesota. Am J Gastroenterol. 2005; 100: A819.
  • 18
    Faubion WA Jr, Loftus EV, Hamsen WS, et al. The natural history of corticosteroid for inflammatory bowel disease: a population-based study. Gastroenterology. 2001; 121: 255260.
  • 19
    Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis. A meta-analysis. Gut. 2001; 48: 526535.
  • 20
    Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007; 13: 123128.